Nucleic Acid Amplification Testing Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Nucleic Acid Amplification Testing Market Analysis
The nucleic acid amplification testing (NAAT) market is poised to grow at a CAGR of 8.3% over the forecast period.
The COVID-19 outbreak has significantly impacted the NAAT market as it was mainly recommended for the detection of a potent SARS-CoV-2 infection was a nucleic acid amplification (NAAT) test that detects one or more specific RNA-specific strains of the virus. According to the study published in Clinical Microbiological Infection in March 2021, in the COVID-19 diagnostic, the overall NAAT sensitivity was 89.1% and the specificity was 98.9%. As a result of the exceptional sensitivity and specificity of NAAT testing in the diagnosis of COVID-19, the demand for such tests spiked amid the pandemic. Therefore, the market during the pandemic might have been significantly impacted due to rise in sales of the NAAT test. Furthermore, the market is expected to show significant growth post-pandemic owing to the emergence of multiple strains of the COVID-19 viruses and other infectious diseases.
The major factors for the growth of the nucleic acid amplification testing (NAAT) market include the rising prevalence of infectious diseases, increasing demand for advanced diagnostic measures, and rising investment in the development of new biotechnological diagnostic techniques.
There is a high prevalence of infectious diseases such as tuberculosis and HIV, which are further responsible for the increasing demand for diagnostic tests, thereby positively impacting the growth of the studied market. For instance, as per the WHO in October 2022, an estimated 10.6 million people fell ill with tuberculosis(TB) worldwide in 2021. Among them 6 million are men, 3.4 million are women and 1.2 million are children. Thus, such a huge prevalence of infectious diseases such as tuberculosis is expected to propel the market's growth due to the rise in NAAT testing adoption.
Rising investments, adoption of key strategies, and product launches are further expected to drive the market in the future. For instance, in December 2021, Roche launched infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni-Utility Channel kit. Cobas HIV-1/HIV-2 Qualitative is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of HIV-1 and HIV-2 in human serum, plasma, and dried blood spots. Such launch of innovative products for NAAT testing is expected to drive market growth due to increased adoption.
Thus, all the aforementioned factors such as rising prevalence of infectious diseases, rising initiatives of key market players in the launch of diagnostics for NAAT, and rising investments in new biotechnological diagnostic tests are expected to boost the market's growth over the forecast period. However, a lack of skilled professionals and higher costs associated with these tests may restrain the market's growth.
Nucleic Acid Amplification Testing Market Trends
This section covers the major market trends shaping the Nucleic Acid Amplification Testing Market according to our research experts:
The Infectious Disease Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi. The diseases can spread, directly or indirectly, from one person to another. The common infectious diseases are strep throat and urinary tract infections (caused by bacteria), HIV/AIDS, the common cold (caused by a virus), influenza, STIs, tuberculosis, and athlete's foot (common fungus), among others.
According to the World Health Organization in August 2022, sexually transmitted infections (STIs) have a significant impact on sexual and reproductive health worldwide and over 1 million STIs are acquired every day in the world. Furthermore, according to the same source, 374 million new infections are estimated with STIs such as chlamydia, gonorrhea, syphilis, and trichomoniasis every year in the world. Thus, such a high incidence of infectious diseases is expected to increase the demand for NAAT testing, driving the market growth over the forecast period.
Furthermore, according to the study published in Infectious Medicine in March 2022, the NAAT has higher sensitivity in the detection of tuberculosis compared to other diagnostic tests such as smear and culture tests. The high sensitivity of this test in the detection of infectious diseases such as tuberculosis is expected to drive segment growth due to its increased adoption in tuberculosis testing.
Thus, the rising prevalence of various infectious diseases and the rising importance of NAAT in the diagnosis of infectious diseases is expected to boost the segment's growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
The North American region is expected to dominate the global market owing to the presence of better healthcare infrastructure, the presence of prominent market players, and the rising prevalence of infectious and chronic diseases.
For instance, according to the ACS Cancer Facts & Figures 2022, around 1,918,030 new cancer cases are estimated to be reported in the United States in the year 2022. Furthermore, according to Statistics Canada in June 2022, it is estimated that around 233,900 people in Canada will be diagnosed with cancer in 2022. The huge cancer burden is increasing the need for diagnostic tests like NAAT driving the market growth in the region.
Additionally, a few of the key market players in the country are developing advanced diagnostics kits to compete with the existing products, while others are acquiring and partnering with the other companies trending in the market. For instance, in September 2022, BD and CerTest Biotec developed a molecular polymerase chain reaction (PCR) assay for the monkeypox virus. Such developments are further bolstering the market growth in the region due to the increased adoption of NAAT testing.
Furthermore, in November 2022, Pulse Scientific was named the national distributor in Canada for Covid-19 & Flu at-home molecular tests developed by Lucira Health. The Lucira testing platform is a Nucleic Acid Amplification Test (NAAT) with sensitivity and specificity comparable to lab-based PCR assays. Therefore, the rising distribution of NAAT in Canada is expected to drive market growth in the region due to the rise in adoption by people for testing infectious diseases conveniently at home.
Thus, the above-mentioned factors such as the rising prevalence of cancers, and rising initiatives from the key market players in launching their products are expected to witness high growth.
Nucleic Acid Amplification Testing Industry Overview
The nucleic acid amplification testing (NAAT) market is moderately fragmented. The factors owing to the competition include rising infectious diseases, the rising launch of products, and rising partnerships between key players, among others. Some of the market players are Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Grifols SA, Hoffmann-La Roche Ltd., Hologic Inc., and Illumina Inc
Nucleic Acid Amplification Testing Market Leaders
-
bioMérieux SA
-
Hoffmann-La Roche Ltd
-
Abbott Laboratories
-
Bio-Rad Laboratories, Inc.
-
Grifols SA
*Disclaimer: Major Players sorted in no particular order
Nucleic Acid Amplification Testing Market News
- In October 2022, Sherlock Biosciences and Harvard University's Office of Technology Development entered an agreement for a global license for a technology that allows nucleic acid molecules to be amplified at room temperature.
- In May 2022, Abbott's ID Now COVID-19 2.0 quick point-of-care test has been given Emergency Use Authorization by the United States Food and Drug Administration. The test is done on the company's ID Now technology, which uses isothermal nucleic acid amplification to detect infectious illnesses qualitatively.
Nucleic Acid Amplification Testing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Infectious Diseases
- 4.2.2 Increasing Demand for Advanced Diagnostic Measures
- 4.2.3 Rising Investment for the Development of New Biotechnological Diagnostic Techniques
-
4.3 Market Restraints
- 4.3.1 Lack of Skilled Professionals
- 4.3.2 High Costs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Technique
- 5.1.1 Target Amplification
- 5.1.2 Probe Amplification
- 5.1.3 Signal Amplification
-
5.2 By Application
- 5.2.1 Infectious Disease
- 5.2.2 Cancer
- 5.2.3 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Becton, Dickinson and Company
- 6.1.3 bioMérieux SA
- 6.1.4 Bio-Rad Laboratories Inc.
- 6.1.5 Grifols SA
- 6.1.6 Hoffmann-La Roche Ltd
- 6.1.7 Hologic Inc.
- 6.1.8 Illumina Inc.
- 6.1.9 Siemens Healthcare GmbH
- 6.1.10 Beckman Coulter Inc. (Danaher Corporation)
- 6.1.11 Tecan Trading AG
- 6.1.12 Seegene Inc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNucleic Acid Amplification Testing Industry Segmentation
As per the scope of this report, nucleic acid amplification tests (NAAT) are used to detect a particular nucleic acid in virus, or bacteria that acts as a pathogen in blood, tissue, and urine. These tests are effective because of their ability to detect very small concentrations of a nucleic acids. The Nucleic Acid Amplification Testing (NAAT) Market is Segmented by Technique (Target Amplification, Probe Amplification, and Signal Amplification), Application (Infectious Disease, Cancer, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Technique | Target Amplification | |
| Probe Amplification | ||
| Signal Amplification | ||
| By Application | Infectious Disease | |
| Cancer | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Nucleic Acid Amplification Testing Market Research FAQs
What is the current Nucleic Acid Amplification Testing (NAAT) Market size?
The Nucleic Acid Amplification Testing (NAAT) Market is projected to register a CAGR of 8.30% during the forecast period (2024-2029)
Who are the key players in Nucleic Acid Amplification Testing (NAAT) Market?
bioMérieux SA, Hoffmann-La Roche Ltd, Abbott Laboratories, Bio-Rad Laboratories, Inc. and Grifols SA are the major companies operating in the Nucleic Acid Amplification Testing (NAAT) Market.
Which is the fastest growing region in Nucleic Acid Amplification Testing (NAAT) Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Nucleic Acid Amplification Testing (NAAT) Market?
In 2024, the North America accounts for the largest market share in Nucleic Acid Amplification Testing (NAAT) Market.
What years does this Nucleic Acid Amplification Testing (NAAT) Market cover?
The report covers the Nucleic Acid Amplification Testing (NAAT) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Nucleic Acid Amplification Testing (NAAT) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Nucleic Acid Amplification Testing (NAAT) Industry Report
Statistics for the 2024 Nucleic Acid Amplification Testing (NAAT) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Nucleic Acid Amplification Testing (NAAT) analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
